RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function. PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on blood vessel function in postmenopausal women with breast cancer.
OBJECTIVES: * Determine the effect of adjuvant aromatase inhibitor therapy on endothelial function in postmenopausal women with breast cancer. OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups according to breast cancer hormone-receptor status (positive vs negative). * Group 1 (hormone receptor-positive): Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity. * Group 2 (hormone receptor-negative): Patients do not receive adjuvant treatment. Endothelial function is measured in both groups at baseline and at follow up by the room temperature peripheral arterial tonometry (RT-PAT) index using the EndoPAT method.
Study Type
OBSERVATIONAL
Enrollment
109
Patients receive aromatase inhibition therapy.
Patients receive aromatase inhibition therapy.
Patients receive aromatase inhibition therapy.
Mayo Clinic
Rochester, Minnesota, United States
Endothelial dysfunction as a result of aromatase inhibitor therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Endothelial function is measured